Jingsong Wang – Founder, Chairman & CEO, Harbour BioMed
2024 marks a moment of inflection for Harbour BioMed, as the company collect the rewards of a strong global execution. In this interview, Dr Jingsong Wang reflects on the strategic,…
Address: Am Klopferspitz 19 – 82152 Martinsried,Germany
Tel: +49 (0) 89 89 96 79-0
BioM is a service and consulting company whose aim is to promote the development of the Munich Biotech Cluster as an internationally renowned centre of excellence in the field of innovative biotechnology. It is the first point of contact for biotech start-up companies seeking financial support or business advice. Through the BioM network which includes all important players in the region (representatives from public offices, scientific institutions, venture capitalists and biotech companies), BioM assists Munich-based companies in finding the right contacts and partners.Part of an additional service offered by BioM is the organization of seminars and workshops on a broad range of topics relevant to the successful development of a biotech company. The young firms are also offered the possibility of participating in larger exhibitions, partnering conferences and other events.
2024 marks a moment of inflection for Harbour BioMed, as the company collect the rewards of a strong global execution. In this interview, Dr Jingsong Wang reflects on the strategic,…
Amr Kenawi, General Manager at Zimmer Biomet in Saudi Arabia, shares his perspective on the country’s evolving healthcare landscape and the company’s role in supporting Vision 2030. Kenawi discusses Zimmer…
Dr Yingjia Zhang and Simon Hua of leading China-based CRO Biometas delve into the company’s rapid expansion in the preclinical space, strategic growth plans, and its positioning in the global…
Vincent Chan, VP and GM of bioMérieux Greater China, shares insights into how the microbiology diagnostics company’s presence has evolved in China over the course of 30 years to today…
Thomas Wirth shares insights into Biomed’s strategic focus on the Swiss pharmaceutical market, offering comprehensive services from regulatory support to market access for RX and OTC products. He discusses Biomed’s…
Fadi Ghanayem, Managing Director for Saudi Arabia and Caucasus, Central Asia, Iran and Mongolia (CCAIM) at French diagnostics firm BioMérieux discusses the remarkable growth he has witnessed in Saudi Arabia…
ENEA Tech and Biomedical is a foundation supervised by the Italian Ministry of Economic Development that aims to strengthen Italian R&D and the industrial transformation of the country’s biomedical sector.…
Professor Ng Huck Hui of A*Star’s Biomedical Research Council outlines the evolution of Singapore’s science and technology research and innovation ecosystem over the past 20 years and why the country…
Clarence Ngui describes how global orthopaedic product giant Zimmer Biomet has pivoted in APAC in response to the COVID-19 pandemic; how medical education needs differ across the vast APAC region;…
Professor Susan M. Gasser, now director and group leader emeritus of the Friedrich Miescher Institute for Biomedical Research (FMI), shares the crucial aspects behind the FMI’s world-class reputation in basic…
Yan Tan, CEO of Xbiome, the first AI-based microbiome drug development company in China, outlines the rationale behind the firm’s founding, what makes its technology platform unique, and the challenges…
Ronald Boueri of Zimmer Biomet Middle East discusses the challenges of establishing the business, the importance of providing the latest innovation and assistance to medical professionals in the MENA (Middle…
Louis Cheng, CEO of Taiwanese firm Leadgene Biomedical, introduces the company’s expertise in antibody technologies, his ambitious internationalization plans, and comments on the vital role that companies like Leadgene have…
PharmaBoardroom caught up with Dr Jingsong Wang, chairman & CEO of Harbour BioMed to discuss the exciting clinical and commercial milestones of the prolific biotech in the last year since…
Rostislav Hartman, general manager of the Czech Republic for Zimmer Biomet and who also looks after numerous countries in a dynamic region in Eastern Europe, introduces Zimmer Biomet’s historical presence…
David López García, Mexico country manager of global rare genetic therapy player Biomarin, outlines the challenging situation around patient access to orphan drugs in Mexico and the importance of building…
Polly Lin, CEO of Guzip Biomarkers, discusses Guzip’s work in epigenetics and the role of DNA methylation in treating endometrial cancer. She highlights the benefits of MPap for women’s health…
Shing-Mou Lee, founder and president of EMO Biomedicine, the leading CDMO provider of cell-based products in Taiwan, discusses the major regulatory and maturation trends in the region and shares his…
Brijesh Sawlani, general manager for North ASEAN Thailand, Myanmar and Indochina at bioMérieux, discusses current opportunities for the Thai affiliate, the competitive landscape in Thailand, his key strategic objective to…
Francois Cornu, president of Eurofins Biomnis, and Gautier Decock, managing director of Eurofins BioPharma Product Testing in France and Belgium, come together to shed light on the company’s unique decentralized…
Dr Jan-Mou Lee, founder of FullHope Biomedical, shares his story of how he came to establish his company after a realization about the loss of impact that occurs when critical…
Harbour BioMed is a fast-growing global biotech company with facilities in Rotterdam, Boston and Shanghai. The company is laser-focused on developing both proprietary and in-licensed immunological therapies using their state-of-the-art…
Jack Wang, founder and CEO of Biomobie, shares the inspirational story behind the establishment of the company, the regenerative principle driving the technology of the Bioboostie device, and the innovative…
Nadia Oka-Bousbia of bioMérieux Algeria discusses the affiliate’s important role within Algeria’s fight against infectious diseases and the training of health managers, difficulties surrounding import restrictions, and the company’s constantly-evolving…
Prof. Michael Yang, an accomplished scientist and start-up expert, introduces the goals of the fast-growing Biomedical Sciences Department of City University Hong Kong. He unveils the contribution of Hong Kong…
Zhang Guojian and Zhang Erying of in-vitro diagnostics manufacturer KingFocus Biomedical, introduce their company’s innovative ‘quantum dots’ technology, its development, client list, and the benefits of being based in Shenzhen.…
Dr. Grace Zhou, dean of SIIBR, discusses the Institute’s priorities, the benefits of being located in Shenzhen and the city’s potential as a global innovation hub. Zhou also outlines the…
Referring to the Canadian affiliate of Zimmer Biomet as a “trailblazer”, Dave O’Neil looks back on a successful 2017 for the musculoskeletal healthcare company in Canada. He describes how Zimmer…
Heraldo Marchezini, CEO of the Brazilian biotech company Biomm and one of the leading executives in the Brazilian biopharmaceutical sector, provides insights into the eye-catching international partnerships recently signed by…
Rocío Mendez, country manager at bioMérieux Colombia, speaks about the many talents that make up the Colombian affiliate and explains how the company brings life-saving and innovative solutions to a…
The Hon. Fanny Law Fan Chiu-fun, chairperson, and Prof. Daniel Lee, head of the Biomedical Technology Cluster, at Hong Kong Science and Technology Parks Corporation (HKSTP) discuss Hong Kong’s potential…
Michael H.J. Lai, Founder of Body Organ Biomedical Corporation, discusses Ologen’s success as the first ever eye tissue repair product and highlights the importance of global exposure for Taiwan-based companies.…
Jassy Wang, CEO of MegaPro Biomedical, a nanomedicine development company specializing in developing nanoparticles and nanomicelles, discusses the evolving nanomedicine market in Taiwan and reveals the company’s plans for future…
Marco Cid, Director General of Investigacion Biomedica, shares how he successfully launched an innovative clinical research center (CRC) despite a challenging regulatory environment. He speaks about the inspiration behind his…
The General Manager of bioMérieux Switzerland and Austria highlights the significance of Switzerland for the company’s regional cluster and furthermore explains how Switzerland contributes to the global development of the…
María Teresa Lopez, managing director at Zimmer Biomet Mexico, discusses the medtech company’s strong commitment to Mexico as well as the high added value of its broad and innovative health…
Howard Lee, chairman and CEO of Easywell Biomedicals, documents the most exciting R&D projects that will drive the company to new heights; spanning from a life-changing Parkinson’s transdermal patch to…
James Lennertz, Group VP and GM EUMEA for BioMarin, discusses the key highlights of the past few years for BioMarin, their unique positioning as a company offering innovative therapies for…
In an exclusive interview with Stephen Ooi, Senior Executive Advisor at Zimmer Biomet, he emphasizes the strategic benefits of the global merger between Zimmer and Biomet and how through leveraging…
Motivated by the transformative role of big data in healthcare, founder and CEO of Vishuo Biomedical, Dongliang Guo discusses the inspiration behind the company, the successful path to commercialization, as well…
Rudi Balling discusses his distinguished career in the life sciences, the LCSB’s mission, and Luxembourg’s burgeoning reputation as a biomedicine, interdisciplinary research, and scientific innovation hub. Earlier this year you…
Renaud Jonquieres, Vice President Asia-Pacific of bioMérieux Industry, enthusiastically conveys the company’s scope and significance in the Asia-Pacific region, the competitive landscape, as well as the key strategic objective to…
CEO of Biomed, Dr. Thomas F. Szuran discusses the keys to success for pharma SMEs and the importance of relationship management, investments, and a culture of internal dialogue. Could you…
Attract, Transform, and Create. The Singapore Economic Development Board’s (EDB) director of biomedical sciences, Weng Si Ho highlights these three actions as the primary strategic focuses of the organization from…
Sandra Sánchez, General Manager at PROBIOMED, explains the crucial role that biosimilars will play in the future healthcare system as well as the importance of complying with COFEPRIS’ regulations to…
Professor Dr. Susan M. Gasser of the Friedrich Miescher Institute for Biomedical Research describes FMI’s fundamental connection between academia and industry in Switzerland, the effects of the foundation’s research, notably…
Patricia Ostrosky, general director of the Institute of Biomedical Research in Mexico, details current research subjects and calls for greater collaboration between Mexican universities and the pharmaceutical industry to bring…
Luigi Boggio, President of Assobiomedica, the association representing the medtech industry, and MD of B. Braun Italy, calls on the Italian government to implement a national system that measures the…
Jean-Luc Bélingard, chairman of bioMérieux, reveals how the medical community in France has a unique profile, combining both clinical and technological experience, leading to what he describes as the best…
Healthcare is moving towards an increased level of personalization and active participation of the patient in the decision-making process. Roland van Esch, General Manager of Zimmer Biomet Netherlands, shares his…
Probiomed wants to move to the next level. The recently appointed general director discusses her plans to grow the business and expand internationally, leveraging the company’s in-house developed biotech products…
Your interest in bioinformatics has run though your academic career and now into your business career as CEO and founder of Biomax Informatics; what was your vision for the company…
Once a little-known mRNA pioneer, BioNTech became a household name with its COVID-19 vaccine developed alongside Pfizer. But the German biotech is now pursuing an even bigger transformation — and…
A summary of some of the top stories coming out of Germany’s biopharma industry, including Bayer’s EMA win for its Eylea eye therapy; the oncology deal Merck KGaA has cut…
After February’s snap election that brought Friedrich Merz to power, a coalition between his conservative CDU/CSU bloc and the centre-left SPD has outlined an agreement this month that will serve…
Rainer Westermann, chairman of the Life Sciences Acceleration Alliance e.V. looks out over the choppy waters for life sciences venture capitalists in Europe over 2025. Three key initiatives stand to…
European pharma is at a turning point, with rising cost pressures, regulatory shifts, and supply chain vulnerabilities reshaping the industry. As the new president of Medicines for Europe, STADA’s Stephan…
A roundup of the biggest stories coming out of Germany’s pharma industry, including Bayer’s biggest share price drop in 20 years; Fresenius Kabi’s biosimilar deal with SamChunDang Pharm; Halozyme Therapeutics’…
The latest news from German pharma, including why Merck KGaA is looking to life science M&A; positive outlooks for Bayer and STADA; BioNTech’s move into the AI lab assistant space…
A roundup of some of the biggest stories coming out of German pharma, including Merck’s better-than-expected Q1 earnings; Stada’s possible return to the stock market; CDMO Vetter’s expanded capacity in…
Oskar Möbert, vice president of Veeva OpenData, discusses how standardizing customer reference data and systems organization-wide can help biopharmas scale globally and become more agile in their business. Data…
The biggest pharma industry and healthcare stories from Germany, including the country’s legalisation of cannabis; the MASH potential of Boehringer Ingelheim’s obesity candidate; Bayer’s further share price drop and expansion…
Pharma is rushing to adopt AI-driven tools in the hope of revolutionizing everything from drug discovery to clinical trials, regulatory submissions, and marketing efforts. While AI is the technology du…
Susanne Schaffert’s over 20-year stint at Novartis culminated with her presidency of the Swiss giant’s global oncology division, but when the company underwent a major restructure in 2022, she found…
See our Cookie Privacy Policy Here
